Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1990-09-13
1993-01-19
Rivers, Diana G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514253, 514279, 514283, 540481, 540597, 544361, 546 41, 546 48, A61K 3147, C07D49122
Patent
active
051807220
ABSTRACT:
A camptothecin analog having the structure shown below: ##STR1## where Z is H or C.sub.1-8 alkyl and R is NO.sub.2, NH.sub.2, N.sub.3, hydrogen, halogen, COOH, OH, O--C.sub.1-3 alkyl, SH, S--C.sub.1-3 alkyl, CN, CH.sub.2 NH.sub.2, NH--C.sub.1-3 alkyl, CH.sub.2 --NH--C.sub.1-3 alkyl, N(C.sub.1-3 alkyl).sub.2, CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O--, NH--, or S--CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S-- CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 CH.sub.2 OH.sub.2).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CHO, C.sub.1-3 alkyl or NHCOCHR.sup.1 NR.sup.2 R.sup.3, where R.sup.1 is the side-chain of an .alpha.-amino acid and R.sup.2 and R.sup.3, independently are hydrogen or a lower alkyl group or R.sup.3 is a peptide unit containing 1-3 amino acid units bonded to the nitrogen through a peptide bond; NHCO--C.sub.2-8 -alkylene--X or NHCO--C.sub.2-8 -alkenylene--X, where X is COOH; CONR.sup.2 --(CH.sub.2).sub.n --NR.sup.2 R.sup.3, where n=1-10 and R.sup.2 and R.sup.3 are as defined above; NHCO--B--(CH.sub.2).sub.n --NR.sup.2 R.sup.3, where B=oxygen or NH, or ##STR2## where m+y=3-6, and salts thereof.
REFERENCES:
patent: 4031986 (1977-06-01), Sugasawa
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4545880 (1985-10-01), Miyasaka et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 4894456 (1990-01-01), Wall et al.
patent: 4914205 (1990-04-01), Sawada et al.
patent: 4981968 (1991-01-01), Wall et al.
patent: 5049668 (1991-09-01), Wall et al.
patent: 5053512 (1991-10-01), Wani et al.
patent: 5106742 (1992-04-01), Wall et al.
Yang, et al. (AR13), Chemical Abstracts, vol. 100: 139434w (1984).
Pan, et al. (AR14), Chemical Abstracts, vol. 84: 115629p (1976).
Wani, et al. J. Med. Chem., vol. 29, No. 11, pp. 2358-2363 (1986).
Wall, et al., J. Am. Chem. Soc., vol. 88, No. 16, pp. 3888-3890 (1966).
Cancer Research, (1989), vol. 49, 4385-5489, "DNA Topoisomerase I-Meditated DNA Cleavage and Cytotixicity of Camptothecin Analogues", Hisang et al.
Cancer Research, (1989), vol. 49, 1465-1469, "Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I . . . " Jaxel et al.
The Journal of Biological Chemistry, (1985, 260, 14873-14878, "Camptothecin Induces Protein-Linked DNA Breaks Via Mammalian DNA Topoisomerase I" Hsiang et al.
J. Med. Chem, (1980), 23, 544-560, "Plant Antitumor Agents. 18..sup.1 Synthesis and Biological Activity of Camptothecin Analogues", Wani et al.
J. Med. Chem, (1986), 29, 1553-1555, "Plant Antitumor Agents 22..sup.1 Isolation of 11-Hydroxycamptothecin from Camptotheca acuminata Decne . . . " Wall et al.
Journal of Labelled Compounds and Radiopharmaceuticals, (1981), 18, 319-329, "The Preparation of Tritium and Deuterium-Labelled Camptothecin", Ronman et al.
J. Medicinal Chemistry, (1987), 30, 1774-1779, "Plant Antitumor Agents 25..sup.1 Total Synthesis and Antileukemic Activity of Ring A . . . ", Wani et al.
J. Medicinal Chemistry, (1990), 33, 972-978, "Plant Antitumor Agents. 29..sup.1 Synthesis and Biological Activity of Ring D and Ring 3 . . . " Nicholas et al.
J. Org. Chem. (1974), 39, 303-311, "Synthesis of Some DE and CDE Ring Analogs of Camptothecin", Plattner et al.
J. of Am. Chem. Soc. (1972), 94, 8615, "Synthesis of Some DE and CDE Ring Analogs of Camptothecin" Plattner et al.
J. Org. Chem., (1974), 39, 3430-3432, "Synthesis of Biological Evaluation of De-AB-Camptothecin", Danishefsky et al.
Govindachari et al, "9-Methoxycamptothecin. A New Alkaloid From Mappia foetida Miers" Indian J. Chem. vol. 110(4), 453-454 (1972).
Proc. Annu. Meet. Am Assoc. Cancer Res, (1988), 29, A1080, "Structure-Activity Study of the Relation Between Topoisomerase I Inhibition and Antitumor . . . " Abstract.
Proc. Annu. Meet. Am Assoc. Cancer Res, (1989), 8, A1019, "A Clinical Study of a Camptothecin Derivative, CPT-11 on Hematological Malignancies", (Mtg Abstract).
Proc. Ann. Meet. Am Assoc. Cancer Res, (1989), 30, A2485, "Irreversible Trapping of the DNA-Topoisomerase I Covalent Complex and Affinity Labeling of . . . " Abstract.
J. Med. Chem, (1989), 32, 715-720, "Modification of the Hydroxy Lactone Ring of Camptothecin: Inhibition of Mammalian Topoisomerase I and . . . ", Mong et al. Abstract.
Science, (1989), 246, 1046-1048, "DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts", Giovanella et al.
Proc. Annu. Meet Am. Assoc. Cancer Res., (1989), A2476, "Structure-Activity Studies of 20(S)-Captothecin Analogs" (Meeting Abstract).
Manikumar Govindarajan
Nicholas Allan W.
Wall Monroe E.
Wani Mansukh C.
Research Triangle Institute
Rivers Diana G.
LandOfFree
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenediox does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenediox, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenediox will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-102230